Press Releases

Filters
February 26, 2019

Debiopharm International SA Initiates a Clinical Trial Phase II study evaluating afabicin in Bone and Joint Infections

Read more
February 14, 2019

Debiopharm International SA Initiates FUZE, a Clinical Trial Phase II study evaluating Debio 1347 in Advanced Solid Tumors harboring an…

Read more
January 7, 2019

Debiopharm Group regains the commercial rights to Trelstar® (Triptorelin pamoate) and looks for new partners in North America

Read more
October 11, 2018

Debiopharm International SA and the Paul Scherrer Institute announce a licensing agreement for the development of a novel targeted radiotherapeutic…

Read more
May 8, 2018

FDA Grants Fast Track designation to Debiopharm International’s Debio 1347 for the treatment of patients with unresectable or metastatic tumors…

Read more
November 22, 2017

Debiopharm International SA Launches Clinical Trials Website for Patients: patients.debiopharm.com

Read more
November 14, 2017

EMA grants Orphan Drug Designation to Debiopharm International SA’s FGFR inhibitor Debio 1347 in the treatment of biliary tract cancer

Read more
November 6, 2017

Debiopharm International SA Announces Dosing of First Patient in a Combination Trial of Debio 1143 and Avelumab in Patients with…

Read more
October 3, 2017

Arbor Pharmaceuticals, LLC and Debiopharm International SA Announce Commercial Availability of Triptodur™, Triptorelin 6-month Formulation, for Treatment of Central Precocious…

Read more